Bortezomib, particularly in a combinatorial approach using either glycogen synthase kinase-3β (GSK3β) inhibitor or radiation, causes the downregulation of HLA molecules and upregulation of NKG2D expression in cancer cells (Lee et al., 2018). This evidence concerns the gene KLRK1 and cancer.